AstraZeneca stomach cancer drug cuts death risk by 42% in late-stage study

AstraZeneca's Sonesitatug vedotin reduced the risk of death by 42% in second- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in the CLARITY-Gastric01 late-stage study, meeting the bar for extending overall survival.

Detected & updated continuously · Source: Nebula